收藏切换
Exploration study on the dosage of recombinant human erythropoietin-Fc in the treatment of renal anemia in Chinese hemodialysis patients
收藏切换
Jianing WANG1, Wenmei ZHANG1, Chun YANG1, Xiaowen LI1, Xinlei GUO1, Li ZUO2, *
World Clinical Drug | 2025, 46(11) : 1127 - 1132
Less
收藏切换
World Clinical Drug | 2025, 46(11): 1127-1132
• Article •
Exploration study on the dosage of recombinant human erythropoietin-Fc in the treatment of renal anemia in Chinese hemodialysis patients
Full
Jianing WANG1, Wenmei ZHANG1, Chun YANG1, Xiaowen LI1, Xinlei GUO1, Li ZUO2, *
Affiliations
  • 1.Sichuan Luzhou Bucang Biopharmaceutical Co., LTD., Luzhou 646111, Sichuan Province, China
  • 2.Department of Nephrology, Peking University People's Hospital, Beijing 100044, China
Published: 2025-11-10 doi: 10.13683/j.wph.2025.11.006
Outline
收藏切换
Objective

To evaluate the clinical efficacy of recombinant human erythropoietin-Fc (rhEPO-Fc) at different doses and frequencies in Chinese patients with renal anemia receiving maintenance hemodialysis (MHD).

Methods

A total of 180 patients with RA receiving MHD from 41 research centers across the country from February 2018 to May 2019 were included. Patients were randomly assigned to the rhEPO-Fc 18 μg/kg per week group, rhEPO-Fc 24 μg/kg per week group, and rhEPO-Fc every 2 weeks 24 μg/kg group by block randomization, with 60 cases in each group. All patients were treated with rhEPO-Fc for 12 weeks, during which the dosage was adjusted according to hemoglobin (Hb).The outcome measures included the Hb level, reticulocyte count and number of dose adjustments.

Results

After treatment, the proportions of patients whose Hb increased by at least 10 g/L or reaching 110 g/L in the three groups were 73.60%, 77.60% and 52.20% respectively. The reticulocyte counts in the three groups increased by (19.63±32.51)×109/L, (18.16±26.24)×109/L and (40.38±27.91)×109/L respectively, compared with before treatment. The proportions of patients who underwent dose adjustment due to decreased Hb levels in the three groups were 73.33%, 56.67% and 63.33%, and 51.67%, 61.67% and 18.33% in patients who underwent dose adjustment due to increased Hb levels.

Conclusion

Administration of rhEPO-Fc once every 1 or 2 weeks can effectively improve the anemia status of MHD patients, and 18 μg/kg per week can be used as the recommended dose for subsequent larger-scale clinical studies.

recombinant human erythropoietin-Fc fusion protein  /  maintenance hemodialysis  /  renal anemia
王家宁, 张文梅, 杨春, 李晓雯, 郭心磊, 左力. 重组人促红细胞生成素-Fc融合蛋白治疗中国血液透析患者肾性贫血剂量探索研究. 世界临床药物, 2025 , 46 (11) : 1127 -1132 . DOI: 10.13683/j.wph.2025.11.006
Jianing WANG, Wenmei ZHANG, Chun YANG, Xiaowen LI, Xinlei GUO, Li ZUO. Exploration study on the dosage of recombinant human erythropoietin-Fc in the treatment of renal anemia in Chinese hemodialysis patients[J]. World Clinical Drug, 2025 , 46 (11) : 1127 -1132 . DOI: 10.13683/j.wph.2025.11.006
Year 2025 volume 46 Issue 11
47
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.11.006
  • Receive Date:2025-05-28
  • Online Date:2026-11-09
  • Published:2025-11-10
Article Data
Affiliations
History
  • Received:2025-05-28
Affiliations
    1.Sichuan Luzhou Bucang Biopharmaceutical Co., LTD., Luzhou 646111, Sichuan Province, China
    2.Department of Nephrology, Peking University People's Hospital, Beijing 100044, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.11.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT